Research programme: cancer stem cell inhibitors - Chugai Pharmaceutical
Latest Information Update: 16 Jul 2016
At a glance
- Originator Chugai Pharmaceutical
- Class
- Mechanism of Action Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cancer metastases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer(Prevention of relapse) in Japan
- 16 Jul 2016 No recent reports of development identified for research development in Cancer-metastases(Prevention) in Japan
- 19 Oct 2012 Early research in Cancer (prevention of relapse) in Japan (unspecified route)